Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betamethason und Salicylsäure (ausschl. Dafo. LOE), f. d. Z. 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betamethason und Salicylsäure (ausschl. Dafo. LOE), f. d”. Bids close on 5 May 2029.
The work
Framework discount agreement for Betamethasone and Salicylic acid (excl. LOE) for DAK-Gesundheit from 01.07.2026 to 30.06.2028.
- Agreement to DAK-Gesundheit's contractual terms and prescribed discounts
Key facts
- Contract period
- 01.07.2026 to 30.06.2028 (with 1x12 month option)
- Evaluation
- Selection based on application letter
What it takes to qualify
Worth a closer look
- § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be borne by the statutory health insurance funds.
- The procedure is not considered to fall within the scope of cartel procurement law due to the lack of a selection decision and the resulting non-discriminatory access for all pharmaceutical companies.
- The contract ends automatically with the entry into force of the exclusive contract.
- The tender document was published using the form for open procedures as no suitable form for approval procedures exists.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- AngebotsschreibenSubmission via email to openhouse@dak.de
- Anerkennung der vertraglichen Maßgaben der DAK-GesundheitSubmission via email to openhouse@dak.de
- Anlage 1 zum VertragSubmission via email to openhouse@dak.de
- Anlage 2 zum VertragSubmission via email to openhouse@dak.de as Excel file